These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 28340246)

  • 1. Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease.
    Panduru NM; Nistor I; Groop PH; Van Biesen W; Farrington K; Covic A
    Nephrol Dial Transplant; 2017 Apr; 32(4):591-597. PubMed ID: 28340246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial and detrimental effects of intensive glycaemic control, with emphasis on type 2 diabetes mellitus.
    Camacho P; Pitale S; Abraira C
    Drugs Aging; 2000 Dec; 17(6):463-76. PubMed ID: 11200307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus-a choice determined by metabolic phenotype.
    Sinclair AJ; Pennells D; Abdelhafiz AH
    Aging Clin Exp Res; 2022 Sep; 34(9):1949-1967. PubMed ID: 35723859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review.
    Noh RM; Graveling AJ; Frier BM
    Expert Opin Pharmacother; 2011 Oct; 12(14):2161-75. PubMed ID: 21668402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of diabetes in metabolic syndrome].
    Pelikánova T
    Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
    Zinman B; Marso SP; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Lange M; Brown-Frandsen K; Moses A; Ocampo Francisco AM; Barner Lekdorf J; Kvist K; Buse JB;
    Diabetologia; 2018 Jan; 61(1):48-57. PubMed ID: 28913575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New hypoglycaemic therapy in frail older people with diabetes mellitus-phenotypic status likely to be more important than functional status.
    Abdelhafiz AH; Emmerton D; Sinclair AJ
    Diabetes Res Clin Pract; 2020 Nov; 169():108438. PubMed ID: 32920102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease.
    Game F
    Nephron Clin Pract; 2014; 126(1):14-8. PubMed ID: 24434725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control.
    Akalin S; Berntorp K; Ceriello A; Das AK; Kilpatrick ES; Koblik T; Munichoodappa CS; Pan CY; Rosenthall W; Shestakova M; Wolnik B; Woo V; Yang WY; Yilmaz MT;
    Int J Clin Pract; 2009 Oct; 63(10):1421-5. PubMed ID: 19769698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
    Inzucchi SE; Zinman B; Wanner C; Ferrari R; Fitchett D; Hantel S; Espadero RM; Woerle HJ; Broedl UC; Johansen OE
    Diab Vasc Dis Res; 2015 Mar; 12(2):90-100. PubMed ID: 25589482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study).
    Weinrauch LA; D'Elia JA; Finn P; Lewis EF; Desai AS; Claggett BL; Cooper ME; McGill JB
    Diabetes Res Clin Pract; 2016 Mar; 113():143-51. PubMed ID: 26830074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management.
    Del Prato S; LaSalle J; Matthaei S; Bailey CJ;
    Int J Clin Pract; 2010 Feb; 64(3):295-304. PubMed ID: 20456169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review on cardiovascular effects of newer hypoglycaemic medications.
    Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
    Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New frontiers in the management of type 2 diabetes.
    Mudaliar S
    Indian J Med Res; 2007 Mar; 125(3):275-96. PubMed ID: 17496356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing awareness of hypoglycaemia in patients with type 2 diabetes treated with oral agents.
    Barnett AH; Brice R; Hanif W; James J; Langerman H
    Curr Med Res Opin; 2013 Nov; 29(11):1503-13. PubMed ID: 23952328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes mellitus in older patients. Is tight blood glucose control warranted?
    Lunt H
    Drugs Aging; 1996 Jun; 8(6):401-7. PubMed ID: 8736623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.